NCT01188967View on ClinicalTrials.gov

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

PHASE2CompletedINTERVENTIONAL

Enrollment

84

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Nicotine Dependence

Interventions

DRUG

GSK598809

Oral dose of 60 mg/day for a treatment period six weeks

DRUG

Placebo

Placebo

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Mclean Hospital

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Massachusetts General Hospital

OTHER